Pacritinib Study Enrolls Adults and Adolescents With MDS and MDS/MPN
A registry record describes a study of oral pacritinib in people aged 12 and older with MDS or MDS/MPN, with treatment potentially continuing for up to eight years.
Posted by Daniel Zaharia | Oct 1, 2026 | Health |
A registry record describes a study of oral pacritinib in people aged 12 and older with MDS or MDS/MPN, with treatment potentially continuing for up to eight years.
Posted by Daniel Zaharia | Sep 30, 2026 | Health |
A ClinicalTrials.gov record lists a study examining music during non-stress testing in pregnant participants, with maternal comfort, vital signs and anxiety named as areas of evaluation. The available information does not include results, enrollment details or a study design.
Read MorePosted by Daniel Zaharia | Sep 29, 2026 | Health |
A pilot clinical research study is evaluating changes in tumor biology after second-line pembrolizumab plus lenvatinib treatment in people with advanced pancreatic ductal adenocarcinoma. The available record does not provide results, enrollment details or safety findings.
Read MorePosted by Daniel Zaharia | Sep 28, 2026 | Health |
A prospective, single-center Phase I study is planned to assess GPRC5D-targeted PET/CT alongside two other imaging approaches in patients with plasma cell disorders.
Read MorePosted by Daniel Zaharia | Sep 28, 2026 | Health |
A trial record describes a study comparing dotinurad with allopurinol in adults with gout-associated hyperuricemia, focused on serum uric acid at Week 24.
Read More